Железодефицитная анемия при заболеваниях желудочно-кишечного тракта


Д.Т. Абдурахманов

Кафедра терапии и профболезней ГБОУ ВПО “Первый МГМУ им. И.М. Сеченова" Минздравсоцразвития РФ, Москва
Обсуждается проблема железодефицитной анемии (ЖДА), развивающейся в т. ч. при заболеваниях желудочно-кишечного тракта. Представлены сведения, касающиеся причин возникновения ЖДА, патогенеза, симптоматики, диагностики и лечения данной патологии. Особое внимание уделено препарату Феринжект (железа карбоксимальтозат), который применяется в комплексной терапии пациентов с ЖДА, обусловленной воспалительными заболеваниями кишечника.

Литература



  1. Gasche C, Lomer MC, Cavill I, Weiss G. Iron, anaemia, and inflammatory bowel diseases. Gut 2004;53:1190-97.

  2. Clark SF. Iron deficiency anemia. Nutr Clin Pract 2008;23:128-41.

  3. Alleyne M, Horne MK, Miller JL. Individualized treatment for iron-deficiency anemia in adults. Am J Med 2008;121:94348.

  4. Simovich M, Hainsworth LN, Fields PA, et al. Localization of the iron transport proteins Mobilferrin and DMT-1 in the duodenum: the surprising role of mucin. Am J Hematol 2003;74:32-45.

  5. Umbreit J. Iron deficiency: a concise review. Am J Hematol 2005;78:225-31.

  6. Guidi GC, Santonastaso CL. Advancements in anemias related to chronic conditions. Clin Chem Lab Med 2010;48(9):1217-26.

  7. Zhu A, Kaneshiro M, Kaunitz JD. Evaluation and Treatment of Iron Deficiency Anemia: A Gastroenterological Perspective. Dig Dis Sci 2010;55:548-59.

  8. Stroehlein JR, Fairbanks VF, McGill DB, Go VL. Hemoccult detection of fecal occult blood quantitated by radioassay. Am J Dig Dis 1976;21;841-44.

  9. Raju GS, Gerson L, Das A, Lewis B. American Gastroenterological Association (AGA) Institute technical review on obscure gastro­intestinal bleeding. Gastroenterology 2007; 133:1697-717.

  10. Pasricha SS, Flecknoe-Brown SC, Allen KJ, et al. Diagnosis and management of iron defi­ciency anaemia: a clinical update. MJA 2010; 193:525-32.

  11. Kulnigg S, Stoinov S, Simanenkov V, et al. A novel intravenous iron formulation for treat­ment of anemia in inflammatory bowel dis­ease: the ferric carboxymaltose (FERINJECT) randomized controlled trial. Am J Gastroenterol 2008;103:1182-92.

  12. Erichsen K, Ulvik RJ, Nysaeter G, et al. Oral ferrous fumarate or intravenous iron sucrose for patients with inflammatory bowel disease. Scand J Gastroenterol 2005;40:1058-65.

  13. Schroder O, Mickisch O, Seidler U, et al. Intravenous iron sucrose versus oral iron sup­plementation for the treatment of iron defi­ciency anemia in patients with inflammatory bowel diseaseea randomized, controlled, open- label, multicenter study. Am J Gastroenterol 2005;100:2503-509.

  14. Evstatiev R, Marteau F, Iqbal T, et al. FERGIcor, a Randomized Controlled Trial on Ferric Carboxymaltose for Iron Deficiency Anemia in Inflammatory Bowel Disease. Gastroenterology 2011;141:846-53.

  15. Van Wyck DB, Martens MG, Seid MH, et al. Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomized controlled trial. Obstet Gynecol 2007;110:267-78.

  16. Van Wyck DB, Mangione A, Morrison J, et al. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial. Transfusion 2009;49:2719-28.

  17. Bailie GR. Efficacy and safety of ferric carboxy­maltose in correcting iron-deficiency anemia: a review of randomized controlled trials across different indications. Arzneimittelforschung 2010;60:386-98.

  18. Evenepoel P, Bako GC, Toma C. Intravenous (i.v.) ferric carboxymaltose (FCM) versus i.v. iron sucrose (ISC) in the treatment of iron deficiency anemia (IDA) in patients undergoing mainte­nance haemodialysis (HD). J Am Soc Nephrol Abstracts Issue 2009;20:665A.


Об авторах / Для корреспонденции


Абдурахманов Д.Т. – д.м.н., проф. кафедры терапии и профболезней ГБОУ ВПО “Первый МГМУ им. И.М. Сеченова” Минздравсоцразвития РФ. E-mail: abdjamal@mail.ru


Похожие статьи


Бионика Медиа